Kissei Pharmaceutical Co., Ltd. (Headquarters: Matsumoto City, Nagano; President & CEO: Mutsuo Kanzawa; hereafter, ”Kissei”) and JCR Pharmaceuticals Co., Ltd. (Headquarters: Ashiya City, Hyogo; Chairman & President, CEO, COO: Shin Ashida; hereafter, ”JCR”)announced the conclusion of a collaborative research and development agreement, for a biosimilar to a long-acting erythropoiesis stimulating agent, “darbepoetin alfa”(generic name), for the treatment of renal anemia.
Kissei and JCR have jointly developed a biosimilar to a recombinant human erythropoietin, “Epoetin alfa BS injection [JCR]”, a treatment agent for renal anemia. It was the first domestically-produced biosimilar in Japan. JCR has manufactured the product and Kissei has distributed it since May 2010.
Both companies are aiming to contribute to the improvement in medical treatment for renal anemia continuously through providing the new economically-efficient treatment option developed under this collaboration with JCR’s global standard quality assurance system and manufacturing system for bio-drugs and Kissei’s established presence in the dialysis field.